Log in to save to my catalogue

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7fc8ddae801d40c48734706dc8c79a42

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

About this item

Full title

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

Publisher

London: BioMed Central Ltd

Journal title

Orphanet journal of rare diseases, 2020-09, Vol.15 (1), p.1-268, Article 268

Language

English

Formats

Publication information

Publisher

London: BioMed Central Ltd

More information

Scope and Contents

Contents

Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction caused by deposition of amyloid light chain fibrils. There are no FDA approved treatments for AL amyloidos...

Alternative Titles

Full title

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_7fc8ddae801d40c48734706dc8c79a42

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7fc8ddae801d40c48734706dc8c79a42

Other Identifiers

ISSN

1750-1172

E-ISSN

1750-1172

DOI

10.1186/s13023-020-01525-2

How to access this item